Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Ariosa Harmony Noninvasive Prenatal Test Gets Coverage From Large Private Insurers in US

NEW YORK (GenomeWeb) – Roche said this week that Ariosa Diagnostics' Harmony noninvasive prenatal test now has in-network status with the four largest national private insurance health plans in the US, increasing its coverage to approximately 200 million covered lives.

A company spokesperson confirmed that the four plans are offered by United Healthcare, Aetna, Cigna, and Anthem.

Roche said the Harmony Prenatal Test is also accessible to patients covered by Medicaid in multiple states, now also including Medi-Cal in California.

"The continued shift toward in-network coverage for the Harmony test is helping to make noninvasive prenatal testing available to more women," said Dave Mullarkey, Ariosa's chief operating officer and lifecycle leader for NIPT, in a statement.

The Harmony test, a blood test available to pregnant women from 10 weeks of gestation, predicts the risk of trisomies 21, 18, and 13 in an fetus. It competes with several other NIPTs, including tests developed by Sequenom, Illumina, and Natera.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.